{"entity":{"id":"nct04300556","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","aka":[],"tldr":"A phase 1/2 trial of Prednisone, Dexamethasone and Lenvatinib in advanced solid tumours, run by Eisai Inc., now recruiting.","summary":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types is a phase 1/2 interventional study registered as NCT04300556 by Eisai Inc., with 182 participants planned, started 2020-08-06 and due to reach its primary completion in 2030-08-08. Interventions recorded: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone and Lenvatinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04300556","url":"https://clinicaltrials.gov/study/NCT04300556"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["prednisone","dexamethasone","lenvatinib"],"companies":["eisai"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04300556","phase":"1/2","setting":"A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types","sponsor":"Eisai Inc.","enrolled":182,"outcomes":[]},"route":"/trials/nct04300556/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"farletuzumab-ecteribulin","kind":"drug","name":"Farletuzumab ecteribulin","route":"/drugs/farletuzumab-ecteribulin/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/"}]}}